WO2023003927A1 - Systems and methods for pathogen detection - Google Patents
Systems and methods for pathogen detection Download PDFInfo
- Publication number
- WO2023003927A1 WO2023003927A1 PCT/US2022/037666 US2022037666W WO2023003927A1 WO 2023003927 A1 WO2023003927 A1 WO 2023003927A1 US 2022037666 W US2022037666 W US 2022037666W WO 2023003927 A1 WO2023003927 A1 WO 2023003927A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- sensor
- pathogen
- conductivity
- conductive material
- antibody
- Prior art date
Links
- 244000052769 pathogen Species 0.000 title claims abstract description 47
- 230000001717 pathogenic effect Effects 0.000 title claims abstract description 43
- 238000000034 method Methods 0.000 title claims description 22
- 238000001514 detection method Methods 0.000 title claims description 13
- 230000008859 change Effects 0.000 claims abstract description 26
- 239000000427 antigen Substances 0.000 claims description 38
- 102000036639 antigens Human genes 0.000 claims description 38
- 108091007433 antigens Proteins 0.000 claims description 38
- 239000004971 Cross linker Substances 0.000 claims description 22
- 239000004020 conductor Substances 0.000 claims description 16
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 13
- 229910021389 graphene Inorganic materials 0.000 claims description 13
- 239000012811 non-conductive material Substances 0.000 claims description 6
- 238000005979 thermal decomposition reaction Methods 0.000 claims description 5
- 241001678559 COVID-19 virus Species 0.000 description 16
- 208000025721 COVID-19 Diseases 0.000 description 10
- 229940096437 Protein S Drugs 0.000 description 10
- 101710198474 Spike protein Proteins 0.000 description 10
- 230000008901 benefit Effects 0.000 description 10
- 238000010586 diagram Methods 0.000 description 8
- 230000035945 sensitivity Effects 0.000 description 7
- 238000012360 testing method Methods 0.000 description 6
- 230000036541 health Effects 0.000 description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 4
- 241000700605 Viruses Species 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 230000026683 transduction Effects 0.000 description 4
- 238000010361 transduction Methods 0.000 description 4
- 230000027455 binding Effects 0.000 description 3
- 238000009739 binding Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 238000000576 coating method Methods 0.000 description 3
- 238000004891 communication Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 210000003296 saliva Anatomy 0.000 description 3
- 238000003860 storage Methods 0.000 description 3
- 239000010936 titanium Substances 0.000 description 3
- 229960005486 vaccine Drugs 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 2
- 239000000443 aerosol Substances 0.000 description 2
- 238000004630 atomic force microscopy Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 238000005530 etching Methods 0.000 description 2
- 239000010931 gold Substances 0.000 description 2
- 229910052739 hydrogen Inorganic materials 0.000 description 2
- 239000001257 hydrogen Substances 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000002687 intercalation Effects 0.000 description 2
- 238000009830 intercalation Methods 0.000 description 2
- 238000012806 monitoring device Methods 0.000 description 2
- 239000002953 phosphate buffered saline Substances 0.000 description 2
- 230000010287 polarization Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 229910010271 silicon carbide Inorganic materials 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 108700022172 2019-nCoV Vaccine mRNA-1273 Proteins 0.000 description 1
- 229910001020 Au alloy Inorganic materials 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 108700022167 ChAdOx1 nCoV-19 Proteins 0.000 description 1
- 241000711573 Coronaviridae Species 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 244000309467 Human Coronavirus Species 0.000 description 1
- -1 JNJ-78436735 Proteins 0.000 description 1
- 229940024452 Janssen COVID-19 vaccine Drugs 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 229940026207 Moderna COVID-19 vaccine Drugs 0.000 description 1
- 229940026232 Novavax COVID-19 vaccine Drugs 0.000 description 1
- 229940025109 Oxford–AstraZeneca COVID-19 vaccine Drugs 0.000 description 1
- 229940026233 Pfizer-BioNTech COVID-19 vaccine Drugs 0.000 description 1
- 101000629318 Severe acute respiratory syndrome coronavirus 2 Spike glycoprotein Proteins 0.000 description 1
- 229910001069 Ti alloy Inorganic materials 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000000089 atomic force micrograph Methods 0.000 description 1
- 229940098773 bovine serum albumin Drugs 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000005611 electricity Effects 0.000 description 1
- 238000005566 electron beam evaporation Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000005669 field effect Effects 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- ZNKMCMOJCDFGFT-UHFFFAOYSA-N gold titanium Chemical compound [Ti].[Au] ZNKMCMOJCDFGFT-UHFFFAOYSA-N 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 229920000729 poly(L-lysine) polymer Polymers 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- RWWYLEGWBNMMLJ-YSOARWBDSA-N remdesivir Chemical compound NC1=NC=NN2C1=CC=C2[C@]1([C@@H]([C@@H]([C@H](O1)CO[P@](=O)(OC1=CC=CC=C1)N[C@H](C(=O)OCC(CC)CC)C)O)O)C#N RWWYLEGWBNMMLJ-YSOARWBDSA-N 0.000 description 1
- RWWYLEGWBNMMLJ-MEUHYHILSA-N remdesivir Drugs C([C@@H]1[C@H]([C@@H](O)[C@@](C#N)(O1)C=1N2N=CN=C(N)C2=CC=1)O)OP(=O)(N[C@@H](C)C(=O)OCC(CC)CC)OC1=CC=CC=C1 RWWYLEGWBNMMLJ-MEUHYHILSA-N 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 239000004065 semiconductor Substances 0.000 description 1
- HBMJWWWQQXIZIP-UHFFFAOYSA-N silicon carbide Chemical compound [Si+]#[C-] HBMJWWWQQXIZIP-UHFFFAOYSA-N 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000001179 sorption measurement Methods 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 238000000859 sublimation Methods 0.000 description 1
- 230000008022 sublimation Effects 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229910001258 titanium gold Inorganic materials 0.000 description 1
Classifications
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
- G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/001—Enzyme electrodes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54366—Apparatus specially adapted for solid-phase testing
- G01N33/54373—Apparatus specially adapted for solid-phase testing involving physiochemical end-point determination, e.g. wave-guides, FETS, gratings
- G01N33/5438—Electrodes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- G—PHYSICS
- G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
- G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
- G16H40/00—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices
- G16H40/60—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices
- G16H40/63—ICT specially adapted for the management or administration of healthcare resources or facilities; ICT specially adapted for the management or operation of medical equipment or devices for the operation of medical equipment or devices for local operation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/165—Coronaviridae, e.g. avian infectious bronchitis virus
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2469/00—Immunoassays for the detection of microorganisms
- G01N2469/10—Detection of antigens from microorganism in sample from host
Definitions
- the present disclosure relates generally to the field of pathogen detection. More specifically, an aspect of the present disclosure provides devices, systems, and methods for wireless sensing of pathogens.
- SARS-CoV-2 the virus responsible for COVID-19
- Remdesivir the first treatment for COVID-19, has shown a prominent effect on inhibiting the early life cycle of coronavirus replication.
- Monoclonal antibodies which target the spike protein of SARS-CoV-2, are another effective treatment for preventing death in high-risk COVID-19 patients.
- Vaccines including BNT162b2, mRNA-1273, JNJ-78436735, AZD1222, and NVX-CoV2373, have been shown to prevent infection or reduce the symptoms of COVID- 19.
- An aspect of the present disclosure provides a system for the detecting of pathogens.
- the system includes a sensor, a processor, and a memory.
- the sensor is configured to generate a signal indicating a conductivity of the sensor.
- the memory includes instructions stored thereon, which, when executed by the processor, cause the system to receive a signal from the sensor, determine a change in a conductivity of the sensor based on the signal, and determine the presence or the absence of a pathogen based on the determined change in conductivity.
- the senor may include quasi-freestanding bilayer epitaxial graphene.
- the instructions when executed by the processor, may further cause the system to compare the signal to a pre-determined conductivity value.
- system may further include a display.
- the instructions when executed by the processor, may further cause the system to display the determined presence or absence of the pathogen.
- the senor may include a first layer of a non-conductive material, a second layer of a conductive material having an antibody bonded thereto, and a set of electrodes disposed on the second layer.
- the antibody may be bonded to the conductive material via a crosslinker.
- the set of electrodes may be configured to supply a charge to the conductive material in the sensor.
- the antibody may correspond to an antigen to be sensed.
- the senor may be reusable.
- the instructions when executed by the processor, may further cause the system to transmit an indication of the determined presence or absence of the pathogen to a user device.
- An aspect of the present disclosure provides a sensor that may include a first layer including a non-conductive material, a second layer including a conductive material having an antibody bonded thereto, and a set of electrodes disposed on the second layer.
- the first layer and the second layer may be formed using thermal decomposition.
- the conductive material may be quasi-freestanding bilayer epitaxial graphene.
- the set of electrodes may be configured to supply a charge to the conductive material.
- the antibody may correspond to an antigen to be sensed.
- the antibody may be chemically bonded to the conductive material via a crosslinker.
- the sensor may be configured to generate a signal indicating a conductivity of the sensor.
- An aspect of the present disclosure provides a computer-implemented method for pathogen detection.
- the computer-implemented method may include determining a change in conductivity of a graphene-based sensor and determining the presence and/or the absence of a pathogen based on the determined change in conductivity.
- the computer-implemented method may further include supplying a charge to a conductive material of the graphene-based sensor using a set of electrodes.
- the computer-implemented method may further include displaying on a user device the determined presence of the pathogen.
- FIG. 1 is a diagram of a system for detecting a pathogen, in accordance with aspects of the disclosure
- FIG. 2 is a block diagram of a controller configured for use with the system for pathogen detection of FIG. 1, in accordance with aspects of the disclosure;
- FIG. 3 is a diagram of a sensor for detecting an antigen, in accordance with aspects of the present disclosure
- FIGS. 4A-D are diagrams illustrating components of the sensor of FIG. 3, in accordance with aspects of the present disclosure.
- FIGS. 5A-B are atomic force microscopy graphs illustrating differences in a composition of the sensor of FIG 3. before and after contact with the antigen, in accordance with aspects of the disclosure
- FIG. 6 is a block diagram showing the components of the sensor of FIG. 3 and an exemplary method of making it, including the steps of thermal decomposition and covalent bonding to a spike protein of an antibody corresponding to the antigen, in accordance with aspects of the disclosure;
- FIG. 7 is a graph illustrating the sensitivity and speed of the sensor of FIG. 3 in the presence of the antigen in various concentrations with clear changes in electrical conductivity, in accordance with aspects of the disclosure
- FIG. 8 is a graph illustrating the effectiveness of the sensor in response to several antigen variants of a pathogen, in accordance with aspects of the present disclosure
- FIGS. 9A-C are graphs illustrating the effectiveness of the sensor of FIG. 3 with varying forms of samples introduced, in accordance with aspects of the disclosure.
- FIG. 10 is a flow diagram for a computer-implemented method of pathogen detection in accordance with aspects of the disclosure. DETAILED DESCRIPTION
- the present disclosure relates generally to the field of pathogen detection. More specifically, an aspect of the present disclosure provides devices, systems, and methods for wireless sensing of antigens.
- the system 100 may be configured to sense whether a pathogen is present by sensing for an antigen 350 (FIG. 3) of the pathogen.
- the pathogen may be the COVID-19 virus.
- the antigen may be a surface protein of a virus.
- the system 100 generally includes a controller 200 and/or a sensor 300 configured to receive a sample 360.
- the sensor 300 may be connected to the controller 200 by a connector 110.
- the sensor 300 may be a quasi-freestanding (“QFS”) bilayer epitaxial graphene (“EG”) based sensor.
- Graphene is a single atomic layer of carbon atoms with a relatively high surface area.
- the sene has shown exceptionally high sensitivity, less than about 1 part per billion, with high electrical conductivity and carrier mobility (e.g., about 100,000 cm 2 / Vs theoretically).
- QFS bilayer EG has several advantages, such as improved thickness uniformity, reduced phonon-carrier scattering, and/or higher mobility by hydrogen intercalation compared to conventional EG.
- the sensor 300 may contain four parts: a semi-insulating substrate (e.g., SiC), QFS bilayer EG, a crosslinker with an antibody corresponding to an antigen, and electrodes (FIGS. 4A-D).
- the high quality and uniformity of EG enable the bottom-up direct immobilization of both crosslinker and the spike protein antibodies on EG without any complex transfer methods.
- EG supports large area synthesis (e.g., up to wafer size range) for commercial scale-up.
- the system 100 may include a voltage and/or current source 140 configured to generate a voltage and/or current to be applied across the sensor 300.
- the system 100 may further include a second sensor 150 (e.g., high speed galvanostat circuit, a voltage sensor, and/or a current sensor) configured to measure a conductivity of the sensor 300 (e.g., the graphene sensor) and generate a signal reflecting the conductivity.
- the system 100 may include a display 130 and/or a touch screen 120.
- the touch screen 120 is configured to enable a user to view testing results of the system 100.
- the touch screen 120 may be further configured for enabling a user to assign, for example, a setpoint, a start, and/or a test length.
- the system 100 may be used as a pathogen sensor, which may utilize the conductivity of the sensor 300 to determine the presence or absence of an antigen 350 of a pathogen within a sample. In aspects, the sample may be as small as one copy of the virus.
- the system 100 may be configured to send test results to other devices and systems, such as electronic medical records.
- the test results may be sent through wireless communication or similar means.
- the system 100 may enable the user to set a start point, a setpoint, and/or a test time length.
- the system 100 may be portable to enable convenient, accurate, and/or widespread testing capabilities.
- COVID-19 virus variants are discussed, the disclosed technology may be used to determine the presence or absence of any pathogen with a known associated antigen to which an antibody exists or may be developed.
- controller 200 includes a processor 220 connected to a computer- readable storage medium or a memory 230.
- the controller 200 may be used to control and/or execute operations of the system 100, including the configuration of display 130 and/or touch screen 120.
- the computer-readable storage medium or memory 230 may be a volatile type of memory, e.g., RAM, and/or a non-volatile type of memory, e.g., flash media, disk media, etc.
- the processor 220 may be another type of processor, such as a digital signal processor, a microprocessor, an ASIC, a graphics processing unit (GPU), a field- programmable gate array (FPGA), and/or a central processing unit (CPU).
- processor 220 generally may refer to one or more or any such processing devices.
- network inference may also be accomplished in systems that have weights implemented as memristors, chemically, or other inference calculations, as opposed to processors.
- the memory 230 can be random access memory, read-only memory, magnetic disk memory, solid-state memory, optical disc memory, and/or another type of memory.
- the memory 230 can be separate from the controller 200 and can communicate with the processor 220 through communication buses of a circuit board and/or through communication cables such as serial ATA cables or other types of cables.
- the memory 230 may include computer-readable instructions that are executable by the processor 220 to operate the controller 200.
- the controller 200 may include a network interface 240 to communicate with other computers or a server.
- a storage device 210 may be used for storing data. The disclosed method may run on the controller 200 and/or on a user device, including, for example, on a mobile device, an IoT device, or a server system.
- the sensor 300 generally includes a semi-insulating non-conductive layer 310.
- the semi-insulating non-conductive layer 310 may include silicon carbide on which a conductive EG layer 320 is disposed.
- the conductive EG layer 320 may be disposed on the semi-insulating non-conductive layer 310 through a thermal decomposition process.
- Two or more electrodes 330 may be disposed on the conductive EG layer 320.
- an antibody 340 associated with an antigen of the pathogen that may be detected based on the presence or absence of an antigen 350 in the sample 360
- the sensor 300 may be configured for detecting the presence or absence of the antigen 350 in real-time based on a change in the conductivity of the sensor 300.
- FIGS. 4A-D diagrams illustrating the synthesis and layering of the parts of the sensor 300 are shown.
- the semi-insulating non-conductive layer 310 is formed on a base layer of non-conductive material.
- the non-conductive material may be SiC.
- FIG. 4B shows a conductive EG layer 320 disposed on the semi-insulating non- conductive layer 310 with an etching process. The etching may be performed on an edge side on EG using CF4 plasma with a simple mask.
- high-quality EG may be synthesized through Si sublimation and subsequent hydrogen intercalation on about a 4-inch diameter semi- insulating (0001) -0.1° off-axis 6H-SiC using a horizontal hot-wall reactor.
- the EG/SiC samples may be cleaned with acetone and isopropanol (IPA), rinsed with deionized (DI) water, and/or dried with pure N2.
- IPA acetone and isopropanol
- DI deionized
- a mesa may be etched on the EG samples by CF4 plasma with a simple mask (about 7 mm x about 7 mm) to isolate the EG on SiC.
- FIG. 4C shows the deposition of a set of electrodes 330 disposed on the conductive EG layer 320.
- the electrodes 330 may provide a flow of electricity to the sensor 300.
- the electrodes 330 may be made of any suitable material.
- a titanium gold (Ti/Au) metal stack may be used for the electrodes 330.
- the formation of the mesa may be followed by the deposition of the four contact electrodes (2 mm x 2 mm), Ti/Au (30 nm/220 nm), by electron beam evaporation on EG.
- FIG. 4D shows immobilization of an antibody 340 corresponding to the antigen 350 to be detected, on the conductive EG layer 320.
- the bonding may include using a crosslinker for immobilization of the antibody 340.
- the sensor 300 may use polyclonal antibodies for the antibody EG heterostmcture with the EG layer. The sensor 300 may recognize different epitopes on the same protein antigen, permitting a low limit of detection.
- the crosslinker 0.1% of poly L lysine, may be diluted in DI water to 0.01 %, and the crosslinker and SI antibodies then immobilized on EG.
- the crosslinker may be immobilized on the EG by contacting a solution of the crosslinker with the EG for about one hour at room temperature. Then, the SI protein antibodies may be immobilized onto the crosslinker by adsorption due to hydrophobic interaction between antibody and crosslinker (similar to immunoassay coating process) by exposing the crosslinker to the antibody 340 for about 12 hours at about 4°C after diluting - e.g., the SARS-CoV-2 spike SI protein (about 1:1000 in ELISA coating buffer (lx)).
- the conductive EG layer 320 may include high sensitivity QFS bilayer EG, which may then be etched.
- the high quality and uniformity of the EG may permit the bottom-up direct immobilization of both the crosslinker and the antibody on the EG without complex transfer methods.
- the antibody 340 has high selectivity and may be incorporated onto the conductive EG layer 320 through a crosslinker and an immobilization procedure to ensure stable bonding.
- FIG. 5A shows the QFS bilayer EG on SiC before the addition of the antibody/crosslinker is added.
- the root- mean- square (RMS) roughness of the crosslinker and the QFS bilayer EG in FIG. 5A may be about 0.8 nm and about 0.7 nm, respectively.
- Graph 504 is a 3D view of graph 502. Scale 506 indicates the structural range of graphs 502 and 504.
- FIG. 5B illustrates the atomic force microscope images of SARS-CoV-2 SI spike protein antibody/crosslinker prepared on EG/SiC.
- the immobilized antibody/crosslinker may be uniform and dense on EG, indicating RMS roughness of about 1.9 nm.
- the change between FIG. 5A and FIG. 5B demonstrates the change in the mesa following crosslinker on the EG surface, which bonds the antibody 340 (FIG. 3) to the sensor 300 (FIG. 1) surface.
- Graph 512 is a 3D view of graph 514. Scale 516 indicates the structural range of graphs 512 and 514.
- FIG. 6 illustrates the stepwise configuration of the sensor 300.
- QFS bilayer EG may be synthesized on a semiconductor layer of SiC (e.g., semi-insulating non-conductive layer 310) through thermal decomposition.
- the set of electrodes 330 may include Ti/Au alloy.
- the electrodes 330 may be applied to the EG layer to deliver a charge generated by voltage and/or current source 140 (FIG. 1).
- a coating of crosslinker and a spike protein of an antibody 340 corresponding to the antigen 350 to be detected may be applied to the EG layer to bond to the graphene surface.
- FIG. 7 illustrates the sensitivity of the sensor 300 (FIG. 1) at varied antigen 350 (FIG. 3) concentrations from about one attogram (10 18 grams) to about one microgram (10 6 grams) of the antigen 350 in the sample 360.
- the sensor 300 may respond to as low as one attogram of the antigen 350.
- the sensor 300 may be highly accurate and may provide a sensitivity that is significantly lower than the limit of detection for conventional immunoassays and other biosensors.
- the sensitivity of the sensor 300 when introduced to several variants of the same pathogen within a sample 360 (FIG. 3) is illustrated.
- the sensor 300 may detect four common human coronavirus variants, including 229E 814, HKU1 810, NL63 816, and/or OC43 812.
- the sensor 300 may provide discemable results in less than two minutes.
- the sensitivity of the sensor 300 when introduced to varied forms of sample 360 (FIG. 3) is illustrated.
- the sensor 300 may function with accuracy and speed with a variety of sample types, including mid-turbinate swabs 920, saliva 980, and/or aerosol 950 samples. For each sample type, the sensor 300 may clearly distinguish between pathogen-negative and pathogen-positive samples in seconds.
- FIG. 10 a flow diagram for a method in accordance with the present disclosure for detecting a pathogen is shown as 1000. Although the steps of FIG. 10 are shown in a particular order, the steps need not all be performed in the specified order, and certain steps can be performed in another order.
- FIG. 10 will be described below, with a controller 200 of FIG. 2 performing the operations.
- the operations of FIG. 10 may be performed all or in part by another device, for example, a server, a mobile device, such as a smartphone, and/or a computer system. These variations are contemplated to be within the scope of the present disclosure.
- the sample 360 (FIG. 3) in either mid-turbinate swab 920 (FIG. 9A), saliva 980 (FIG. 9C), aerosol 950 (FIG. 9B), and/or other form is applied to the conductive EG layer 320 (i.e., hetero structure surface including antibody 340, see FIG. 3) of sensor 300 (FIG. 1).
- saliva samples may be stored as is, or may be diluted with lx Phosphate-buffered saline containing about 0.1% bovine serum albumin (PBS/BSA) when the volume is less than about 1 ml..
- strain induced on the QFS EG may create a G-peak shift, enabling the transduction of antibody-antigen bindings.
- a pathogen may be detected based on electrical transduction of the SARS-CoV-2 SI spike protein antigen via SARS-CoV-2 SI spike protein antibodies immobilized on QFS EG. This polarization-induced strain enables the electrical transduction of as little as about 1 attogram per millimeter of the SARS-CoV-2 SI spike protein antigen upon binding with the SARS-CoV-2 SI spike protein antibodies immobilized on QFS EG.
- the conductivity of the sensor 300 may be configured to change based on the presence of an antigen 350 (FIG. 3) of a particular pathogen.
- the controller 200 may supply a charge to the conductive EG layer 320 in the sensor 300 using the set of electrodes 330 (FIG. 3). The charge may be generated by voltage and/or current source 140 (FIG. 1).
- the conductivity of the sensor 300 may increase. For example, an input current of 10 mA may be applied to the sensor 300 directly and maintained during the measurement.
- the detected output electrical response may be normalized as AV/Vo, where AV is the change in voltage and V 0 is the original voltage.
- the controller 200 receives a signal from the sensor 300.
- the signal may indicate a conductivity of the sensor 300.
- the signal may be a voltage, e.g., about 5 volts.
- the second sensor 150 may detect the voltage and the controller 200 may compare the voltage to a stored calibration voltage for the sensor 300.
- the stored calibration voltage may be about 2 volts.
- the controller 200 may compare the sensed 5 volts to the stored calibration voltage of about 2 volts and determine the presence of the antigen 350 based on the difference.
- the second sensor 150 may include a high speed galvanostat circuit.
- the high speed galvanostat circuit may be configured to maintain a constant current through the sensor 300, and then when the resistance of the sensor changes due to interactions with the virus, the galvanostat has to change its compliance voltage to maintain the same current.
- the signal may indicate a conductivity of the sensor 300 may include the changed compliance voltage.
- the controller 200 determines whether there is a change in conductivity of the sensor 300.
- the sensor may have a conductivity of about 0.0 DU/U 0 , where DU is the change in voltage and V 0 is the original voltage.
- the conductivity may change to about 0.5 AV/V o . which is over the threshold of about 0.05 AV/V 0.
- the controller 200 may process the signal to determine if the antigen 350 is absent or present in response to the change in conductivity of the sensor 300.
- the controller 200 may determine that the change in conductivity of the sensor 300 indicates the absence or presence of an antigen 350 of a pathogen being sensed.
- the controller 200 may use a voltage sensor to sense the change in conductivity of the sensor 300.
- the controller 200 may compare the signal to a pre-determined threshold value. For example, a significant change in conductivity may indicate the antigen 350 is present and the sample is positive. For example, no change in conductivity or an insignificant change in conductivity may indicate the pathogen is absent, and the sample is negative. Based on the presence of the antigen 350, the controller 200 may determine that a pathogen is present.
- the spike protein of an antibody 340 may be associated with a common human coronavirus SARS-CoV-2 antigen, which is responsible for the COVID-19 vims.
- the AV/V 0 may indicate the presence of the SARS-CoV-2 by demonstrating an increase in conductivity with a higher voltage passing through the EG.
- the controller 200 displays whether the pathogen is present or absent.
- the display 130 may display that the pathogen is present in the sample by showing an increase in voltage flowing through the conductive EG layer 320 of sensor 300.
- the sensor 300 may be configured to sense SARS-CoV-2, the antigen 350 responsible for the COVID-19 pathogen.
- the antibody EG heterostmcture may consist of an antibody 340 associated with SARS-CoV-2, which may change the EG configuration to be more conductive and to pass more voltage through the conductive EG layer 320 when a SARS-CoV-2 antigen is present in the sample.
- the sensor 300 may provide the benefit of real-time ultra sensitive sensing of pathogens.
- the senor 300 may be reusable.
- the sensor 300 may be cleaned and reused by heating the sensor 300 to a temperature greater than about 40°C.
- the sensor 300 may also be cleaned for reuse by soaking the sensor 300 in a salt solution.
- the controller 200 is configured to wirelessly transmit (e.g., by BluetoothTM or other wireless protocol) the data to a smartphone application.
- the data may be wirelessly transmitted (securely) to other types of authorized systems/devices, including but not limited to local health monitoring devices, remote health monitoring systems (e.g., cloud- based and perhaps operated by a healthcare provider), and/or a combination of a local health monitoring device that provides health monitoring information to a health monitoring system.
- Certain aspects of the present disclosure may include some, all, or none of the above advantages and/or one or more other advantages readily apparent to those skilled in the art from the drawings, descriptions, and claims included herein.
- the various aspects of the present disclosure may include all, some, or none of the enumerated advantages and/or other advantages not specifically enumerated above.
- a phrase in the form “at least one of A, B, or C” means “(A); (B); (C); (A and B); (A and
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Medical Informatics (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Public Health (AREA)
- General Physics & Mathematics (AREA)
- Food Science & Technology (AREA)
- Medicinal Chemistry (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Primary Health Care (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biophysics (AREA)
- Databases & Information Systems (AREA)
- Data Mining & Analysis (AREA)
- Genetics & Genomics (AREA)
- General Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Business, Economics & Management (AREA)
- General Business, Economics & Management (AREA)
- Investigating Or Analyzing Materials By The Use Of Electric Means (AREA)
Abstract
A system for the sensing of pathogens includes a sensor, a processor, and a memory. The sensor is configured to generate a signal indicating a conductivity of the sensor. The memory includes instructions stored thereon, which, when executed by the processor, cause the system to receive the signal from the sensor, determine a change in a conductivity of the sensor based on the signal, and determine the presence or the absence of a pathogen based on the determined change in conductivity.
Description
SYSTEMS AND METHODS FOR PATHOGEN DETECTION
CROSS-REFERENCE TO RELATED APPLICATION/CLAIM OF PRIORITY [0001] This application claims the benefit of, and priority to, U.S. Provisional Patent Application No. 63/223,919 filed on July 20, 2021, the entire contents of which are hereby incorporated by reference.
TECHNICAL FIELD
[0002] The present disclosure relates generally to the field of pathogen detection. More specifically, an aspect of the present disclosure provides devices, systems, and methods for wireless sensing of pathogens.
BACKGROUND
[0003] SARS-CoV-2, the virus responsible for COVID-19, can be highly infectious in recently infected individuals and in asymptomatic carriers, which has led to the global spread of COVID-19. Remdesivir, the first treatment for COVID-19, has shown a prominent effect on inhibiting the early life cycle of coronavirus replication. Monoclonal antibodies, which target the spike protein of SARS-CoV-2, are another effective treatment for preventing death in high-risk COVID-19 patients. Vaccines, including BNT162b2, mRNA-1273, JNJ-78436735, AZD1222, and NVX-CoV2373, have been shown to prevent infection or reduce the symptoms of COVID- 19. However, the reduced effectiveness of the vaccines and monoclonal antibodies in preventing severe illness from variants such as B.1.1.7, B.1.351, B.1.429, B.1.526, B.1.617, and P.l remains a concern. In addition, the global rollout of the vaccines will take time. The key to preventing the spread of COVID-19 is early detection before developing symptoms. Hence, ultrafast, highly sensitive diagnostic methods are needed to prevent the further spread of COVID-19. Real-time
reverse transcription-polymerase chain reaction (RT-PCR), the gold standard for COVID-19 diagnostics, detects infection through the genetic makeup of SARS-CoV-2. However, due to its sophisticated and time-consuming experimental settings, rapid, on-site diagnosis is not feasible. [0004] Accordingly, there is interest in an improved means for pathogen detection.
SUMMARY
[0005] An aspect of the present disclosure provides a system for the detecting of pathogens. The system includes a sensor, a processor, and a memory. The sensor is configured to generate a signal indicating a conductivity of the sensor. The memory includes instructions stored thereon, which, when executed by the processor, cause the system to receive a signal from the sensor, determine a change in a conductivity of the sensor based on the signal, and determine the presence or the absence of a pathogen based on the determined change in conductivity.
[0006] In an aspect of the present disclosure, the sensor may include quasi-freestanding bilayer epitaxial graphene.
[0007] In yet another aspect of the present disclosure, the instructions, when executed by the processor, may further cause the system to compare the signal to a pre-determined conductivity value.
[0008] In another aspect of the present disclosure, the system may further include a display. The instructions, when executed by the processor, may further cause the system to display the determined presence or absence of the pathogen.
[0009] In yet another aspect of the present disclosure, the sensor may include a first layer of a non-conductive material, a second layer of a conductive material having an antibody bonded thereto, and a set of electrodes disposed on the second layer.
[0010] In another aspect of the present disclosure, the antibody may be bonded to the conductive material via a crosslinker.
[0011] In yet another aspect of the present disclosure, the set of electrodes may be configured to supply a charge to the conductive material in the sensor.
[0012] In another aspect of the present disclosure, the antibody may correspond to an antigen to be sensed.
[0013] In yet another aspect of the present disclosure, the sensor may be reusable.
[0014] In another aspect, the instructions, when executed by the processor, may further cause the system to transmit an indication of the determined presence or absence of the pathogen to a user device.
[0015] An aspect of the present disclosure provides a sensor that may include a first layer including a non-conductive material, a second layer including a conductive material having an antibody bonded thereto, and a set of electrodes disposed on the second layer. [0016] In another aspect of the present disclosure, the first layer and the second layer may be formed using thermal decomposition.
[0017] In yet another aspect of the present disclosure, the conductive material may be quasi-freestanding bilayer epitaxial graphene.
[0018] In another aspect of the present disclosure, the set of electrodes may be configured to supply a charge to the conductive material.
[0019] In yet another aspect of the present disclosure, the antibody may correspond to an antigen to be sensed.
[0020] In another aspect of the present disclosure, the antibody may be chemically bonded to the conductive material via a crosslinker.
[0021] In another aspect of the present disclosure, the sensor may be configured to generate a signal indicating a conductivity of the sensor.
[0022] An aspect of the present disclosure provides a computer-implemented method for pathogen detection. The computer-implemented method may include determining a change in conductivity of a graphene-based sensor and determining the presence and/or the absence of a pathogen based on the determined change in conductivity.
[0023] In another aspect of the present disclosure, the computer-implemented method may further include supplying a charge to a conductive material of the graphene-based sensor using a set of electrodes.
[0024] In another aspect, the computer-implemented method may further include displaying on a user device the determined presence of the pathogen.
[0025] Further details and aspects of the present disclosure are described in more detail below with reference to the appended drawings.
BRIEF DESCRIPTION OF THE DRAWINGS
[0026] A better understanding of the features and advantages of the present disclosure will be obtained by reference to the following detailed description that sets forth illustrative aspects, in which the principles of the present disclosure are utilized, and the accompanying drawings of which:
[0027] FIG. 1 is a diagram of a system for detecting a pathogen, in accordance with aspects of the disclosure;
[0028] FIG. 2 is a block diagram of a controller configured for use with the system for pathogen detection of FIG. 1, in accordance with aspects of the disclosure;
[0029] FIG. 3 is a diagram of a sensor for detecting an antigen, in accordance with aspects of the present disclosure;
[0030] FIGS. 4A-D are diagrams illustrating components of the sensor of FIG. 3, in accordance with aspects of the present disclosure;
[0031] FIGS. 5A-B are atomic force microscopy graphs illustrating differences in a composition of the sensor of FIG 3. before and after contact with the antigen, in accordance with aspects of the disclosure;
[0032] FIG. 6 is a block diagram showing the components of the sensor of FIG. 3 and an exemplary method of making it, including the steps of thermal decomposition and covalent bonding to a spike protein of an antibody corresponding to the antigen, in accordance with aspects of the disclosure;
[0033] FIG. 7 is a graph illustrating the sensitivity and speed of the sensor of FIG. 3 in the presence of the antigen in various concentrations with clear changes in electrical conductivity, in accordance with aspects of the disclosure;
[0034] FIG. 8 is a graph illustrating the effectiveness of the sensor in response to several antigen variants of a pathogen, in accordance with aspects of the present disclosure;
[0035] FIGS. 9A-C are graphs illustrating the effectiveness of the sensor of FIG. 3 with varying forms of samples introduced, in accordance with aspects of the disclosure; and [0036] FIG. 10 is a flow diagram for a computer-implemented method of pathogen detection in accordance with aspects of the disclosure.
DETAILED DESCRIPTION
[0037] The present disclosure relates generally to the field of pathogen detection. More specifically, an aspect of the present disclosure provides devices, systems, and methods for wireless sensing of antigens.
[0038] Aspects of the present disclosure are described in detail with reference to the drawings wherein like reference numerals identify similar or identical elements.
[0039] Although the present disclosure will be described in terms of specific aspects and examples, it will be readily apparent to those skilled in this art that various modifications, rearrangements, and substitutions may be made without departing from the spirit of the present disclosure. The scope of the present disclosure is defined by the claims appended hereto.
[0040] For purposes of promoting an understanding of the principles of the present disclosure, reference will now be made to exemplary aspects illustrated in the drawings, and specific language will be used to describe the same. It will nevertheless be understood that no limitation of the scope of the present disclosure is thereby intended. Any alterations and further modifications of the novel features illustrated herein, and any additional applications of the principles of the present disclosure as illustrated herein, which would occur to one skilled in the relevant art and having possession of this disclosure, are to be considered within the scope of the present disclosure.
[0041] Referring to FIG. 1, a system 100 for detecting the presence or absence of a pathogen is shown. The system 100 may be configured to sense whether a pathogen is present by sensing for an antigen 350 (FIG. 3) of the pathogen. In aspects, the pathogen may be the COVID-19 virus. The antigen may be a surface protein of a virus. The system 100 generally includes a controller 200 and/or a sensor 300 configured to receive a sample 360.
The sensor 300 may be connected to the controller 200 by a connector 110. The sensor 300 may be a quasi-freestanding (“QFS”) bilayer epitaxial graphene (“EG”) based sensor. Graphene is a single atomic layer of carbon atoms with a relatively high surface area. Graphene has shown exceptionally high sensitivity, less than about 1 part per billion, with high electrical conductivity and carrier mobility (e.g., about 100,000 cm2/ Vs theoretically). QFS bilayer EG has several advantages, such as improved thickness uniformity, reduced phonon-carrier scattering, and/or higher mobility by hydrogen intercalation compared to conventional EG. In aspects, the sensor 300 may contain four parts: a semi-insulating substrate (e.g., SiC), QFS bilayer EG, a crosslinker with an antibody corresponding to an antigen, and electrodes (FIGS. 4A-D). The high quality and uniformity of EG enable the bottom-up direct immobilization of both crosslinker and the spike protein antibodies on EG without any complex transfer methods. EG supports large area synthesis (e.g., up to wafer size range) for commercial scale-up.
[0042] The system 100 may include a voltage and/or current source 140 configured to generate a voltage and/or current to be applied across the sensor 300. The system 100 may further include a second sensor 150 (e.g., high speed galvanostat circuit, a voltage sensor, and/or a current sensor) configured to measure a conductivity of the sensor 300 (e.g., the graphene sensor) and generate a signal reflecting the conductivity. The system 100 may include a display 130 and/or a touch screen 120. The touch screen 120 is configured to enable a user to view testing results of the system 100. The touch screen 120 may be further configured for enabling a user to assign, for example, a setpoint, a start, and/or a test length. The system 100 may be used as a pathogen sensor, which may utilize the conductivity of the
sensor 300 to determine the presence or absence of an antigen 350 of a pathogen within a sample. In aspects, the sample may be as small as one copy of the virus.
[0043] In aspects, the system 100 may be configured to send test results to other devices and systems, such as electronic medical records. In aspects, the test results may be sent through wireless communication or similar means. The system 100 may enable the user to set a start point, a setpoint, and/or a test time length. The system 100 may be portable to enable convenient, accurate, and/or widespread testing capabilities.
[0044] Although COVID-19 virus variants are discussed, the disclosed technology may be used to determine the presence or absence of any pathogen with a known associated antigen to which an antibody exists or may be developed.
[0045] Referring to FIG. 2 controller 200 includes a processor 220 connected to a computer- readable storage medium or a memory 230. The controller 200 may be used to control and/or execute operations of the system 100, including the configuration of display 130 and/or touch screen 120. The computer-readable storage medium or memory 230 may be a volatile type of memory, e.g., RAM, and/or a non-volatile type of memory, e.g., flash media, disk media, etc. In various aspects of the disclosure, the processor 220 may be another type of processor, such as a digital signal processor, a microprocessor, an ASIC, a graphics processing unit (GPU), a field- programmable gate array (FPGA), and/or a central processing unit (CPU). Further, processor 220 generally may refer to one or more or any such processing devices. In certain aspects of the disclosure, network inference may also be accomplished in systems that have weights implemented as memristors, chemically, or other inference calculations, as opposed to processors.
[0046] In aspects, the memory 230 can be random access memory, read-only memory,
magnetic disk memory, solid-state memory, optical disc memory, and/or another type of memory. In some aspects of the disclosure, the memory 230 can be separate from the controller 200 and can communicate with the processor 220 through communication buses of a circuit board and/or through communication cables such as serial ATA cables or other types of cables. The memory 230 may include computer-readable instructions that are executable by the processor 220 to operate the controller 200. In aspects of the disclosure, the controller 200 may include a network interface 240 to communicate with other computers or a server. A storage device 210 may be used for storing data. The disclosed method may run on the controller 200 and/or on a user device, including, for example, on a mobile device, an IoT device, or a server system.
[0047] With reference to FIG. 3, an illustration of the sensor 300 interacting with a sample 360 is shown. The sensor 300 generally includes a semi-insulating non-conductive layer 310. The semi-insulating non-conductive layer 310 may include silicon carbide on which a conductive EG layer 320 is disposed. The conductive EG layer 320 may be disposed on the semi-insulating non-conductive layer 310 through a thermal decomposition process. Two or more electrodes 330 may be disposed on the conductive EG layer 320. Further, an antibody 340 associated with an antigen of the pathogen (that may be detected based on the presence or absence of an antigen 350 in the sample 360) may be disposed on the conductive EG layer 320. The sensor 300 may be configured for detecting the presence or absence of the antigen 350 in real-time based on a change in the conductivity of the sensor 300.
[0048] Referring to FIGS. 4A-D, diagrams illustrating the synthesis and layering of the parts of the sensor 300 are shown. In FIG. 4A, the semi-insulating non-conductive layer 310 is formed on a base layer of non-conductive material. The non-conductive material may be SiC.
[0049] FIG. 4B shows a conductive EG layer 320 disposed on the semi-insulating non- conductive layer 310 with an etching process. The etching may be performed on an edge side on EG using CF4 plasma with a simple mask. For example, high-quality EG may be synthesized through Si sublimation and subsequent hydrogen intercalation on about a 4-inch diameter semi- insulating (0001) -0.1° off-axis 6H-SiC using a horizontal hot-wall reactor. After dicing the EG/SiC samples (8 mm x 8 mm), the EG/SiC samples may be cleaned with acetone and isopropanol (IPA), rinsed with deionized (DI) water, and/or dried with pure N2. A mesa may be etched on the EG samples by CF4 plasma with a simple mask (about 7 mm x about 7 mm) to isolate the EG on SiC.
[0050] FIG. 4C shows the deposition of a set of electrodes 330 disposed on the conductive EG layer 320. The electrodes 330 may provide a flow of electricity to the sensor 300. The electrodes 330 may be made of any suitable material. For example, a titanium gold (Ti/Au) metal stack may be used for the electrodes 330. The formation of the mesa may be followed by the deposition of the four contact electrodes (2 mm x 2 mm), Ti/Au (30 nm/220 nm), by electron beam evaporation on EG.
[0051] FIG. 4D shows immobilization of an antibody 340 corresponding to the antigen 350 to be detected, on the conductive EG layer 320. The bonding may include using a crosslinker for immobilization of the antibody 340. In an aspect, the sensor 300 may use polyclonal antibodies for the antibody EG heterostmcture with the EG layer. The sensor 300 may recognize different epitopes on the same protein antigen, permitting a low limit of detection. For example, the crosslinker, 0.1% of poly L lysine, may be diluted in DI water to 0.01 %, and the crosslinker and SI antibodies then immobilized on EG. The crosslinker may be immobilized on the EG by contacting a solution of the crosslinker with the EG for about one hour at room temperature.
Then, the SI protein antibodies may be immobilized onto the crosslinker by adsorption due to hydrophobic interaction between antibody and crosslinker (similar to immunoassay coating process) by exposing the crosslinker to the antibody 340 for about 12 hours at about 4°C after diluting - e.g., the SARS-CoV-2 spike SI protein (about 1:1000 in ELISA coating buffer (lx)). [0052] In aspects, the conductive EG layer 320 may include high sensitivity QFS bilayer EG, which may then be etched. The high quality and uniformity of the EG may permit the bottom-up direct immobilization of both the crosslinker and the antibody on the EG without complex transfer methods. The antibody 340 has high selectivity and may be incorporated onto the conductive EG layer 320 through a crosslinker and an immobilization procedure to ensure stable bonding.
[0053] Referring to FIG. 5 A and 5B, atomic force microscopy of a mesa made of EG is shown. FIG. 5A shows the QFS bilayer EG on SiC before the addition of the antibody/crosslinker is added. The root- mean- square (RMS) roughness of the crosslinker and the QFS bilayer EG in FIG. 5A may be about 0.8 nm and about 0.7 nm, respectively. Graph 504 is a 3D view of graph 502. Scale 506 indicates the structural range of graphs 502 and 504.
[0054] FIG. 5B illustrates the atomic force microscope images of SARS-CoV-2 SI spike protein antibody/crosslinker prepared on EG/SiC. The immobilized antibody/crosslinker may be uniform and dense on EG, indicating RMS roughness of about 1.9 nm. The change between FIG. 5A and FIG. 5B demonstrates the change in the mesa following crosslinker on the EG surface, which bonds the antibody 340 (FIG. 3) to the sensor 300 (FIG. 1) surface. Graph 512 is a 3D view of graph 514. Scale 516 indicates the structural range of graphs 512 and 514.
[0055] FIG. 6 illustrates the stepwise configuration of the sensor 300. QFS bilayer EG may be synthesized on a semiconductor layer of SiC (e.g., semi-insulating non-conductive layer 310) through thermal decomposition. The set of electrodes 330 may include Ti/Au alloy. The electrodes 330 may be applied to the EG layer to deliver a charge generated by voltage and/or current source 140 (FIG. 1). A coating of crosslinker and a spike protein of an antibody 340 corresponding to the antigen 350 to be detected may be applied to the EG layer to bond to the graphene surface.
[0056] FIG. 7 illustrates the sensitivity of the sensor 300 (FIG. 1) at varied antigen 350 (FIG. 3) concentrations from about one attogram (10 18 grams) to about one microgram (106 grams) of the antigen 350 in the sample 360. In aspects, the sensor 300 may respond to as low as one attogram of the antigen 350. The sensor 300 may be highly accurate and may provide a sensitivity that is significantly lower than the limit of detection for conventional immunoassays and other biosensors.
[0057] With reference to FIG. 8, the sensitivity of the sensor 300 (FIG. 1) when introduced to several variants of the same pathogen within a sample 360 (FIG. 3) is illustrated. In aspects, the sensor 300 may detect four common human coronavirus variants, including 229E 814, HKU1 810, NL63 816, and/or OC43 812. In aspects, the sensor 300 may provide discemable results in less than two minutes.
[0058] With reference to FIGS. 9A-C, the sensitivity of the sensor 300 (FIG. 1) when introduced to varied forms of sample 360 (FIG. 3) is illustrated. In aspects, the sensor 300 may function with accuracy and speed with a variety of sample types, including mid-turbinate swabs 920, saliva 980, and/or aerosol 950 samples. For each sample type, the sensor 300 may clearly distinguish between pathogen-negative and pathogen-positive samples in seconds.
[0059] Referring to FIG. 10, a flow diagram for a method in accordance with the present disclosure for detecting a pathogen is shown as 1000. Although the steps of FIG. 10 are shown in a particular order, the steps need not all be performed in the specified order, and certain steps can be performed in another order. For example, FIG. 10 will be described below, with a controller 200 of FIG. 2 performing the operations. In aspects, the operations of FIG. 10 may be performed all or in part by another device, for example, a server, a mobile device, such as a smartphone, and/or a computer system. These variations are contemplated to be within the scope of the present disclosure.
[0060] Initially, at step 1010, the sample 360 (FIG. 3) in either mid-turbinate swab 920 (FIG. 9A), saliva 980 (FIG. 9C), aerosol 950 (FIG. 9B), and/or other form is applied to the conductive EG layer 320 (i.e., hetero structure surface including antibody 340, see FIG. 3) of sensor 300 (FIG. 1). For example, saliva samples may be stored as is, or may be diluted with lx Phosphate-buffered saline containing about 0.1% bovine serum albumin (PBS/BSA) when the volume is less than about 1 ml.. Although one sensor is used as an example, multiple sensors may be tested at once, for example, using one breath. In aspects, strain induced on the QFS EG may create a G-peak shift, enabling the transduction of antibody-antigen bindings. For example, a pathogen may be detected based on electrical transduction of the SARS-CoV-2 SI spike protein antigen via SARS-CoV-2 SI spike protein antibodies immobilized on QFS EG. This polarization-induced strain enables the electrical transduction of as little as about 1 attogram per millimeter of the SARS-CoV-2 SI spike protein antigen upon binding with the SARS-CoV-2 SI spike protein antibodies immobilized on QFS EG. These polarization fields have the benefit of enabling the electrical transduction of bindings through a sensor design that does not require the typical field effect transistor architecture.
[0061] The conductivity of the sensor 300 may be configured to change based on the presence of an antigen 350 (FIG. 3) of a particular pathogen. In aspects, the controller 200 may supply a charge to the conductive EG layer 320 in the sensor 300 using the set of electrodes 330 (FIG. 3). The charge may be generated by voltage and/or current source 140 (FIG. 1). In the presence of the antigen 350, the conductivity of the sensor 300 may increase. For example, an input current of 10 mA may be applied to the sensor 300 directly and maintained during the measurement. The detected output electrical response may be normalized as AV/Vo, where AV is the change in voltage and V0 is the original voltage.
[0062] Next, at step 1020, the controller 200 receives a signal from the sensor 300. The signal may indicate a conductivity of the sensor 300. For example, the signal may be a voltage, e.g., about 5 volts. The second sensor 150 may detect the voltage and the controller 200 may compare the voltage to a stored calibration voltage for the sensor 300. For example, the stored calibration voltage may be about 2 volts. The controller 200 may compare the sensed 5 volts to the stored calibration voltage of about 2 volts and determine the presence of the antigen 350 based on the difference. In aspects, the second sensor 150 may include a high speed galvanostat circuit. The high speed galvanostat circuit may be configured to maintain a constant current through the sensor 300, and then when the resistance of the sensor changes due to interactions with the virus, the galvanostat has to change its compliance voltage to maintain the same current. The signal may indicate a conductivity of the sensor 300 may include the changed compliance voltage.
[0063] Next, at step 1030, the controller 200 determines whether there is a change in conductivity of the sensor 300. For example, prior to the sample being placed on the sensor, the sensor may have a conductivity of about 0.0 DU/U0, where DU is the change in voltage and V0 is
the original voltage. After a positive sample is introduced, the conductivity may change to about 0.5 AV/Vo. which is over the threshold of about 0.05 AV/V0. The controller 200 may process the signal to determine if the antigen 350 is absent or present in response to the change in conductivity of the sensor 300. The controller 200 may determine that the change in conductivity of the sensor 300 indicates the absence or presence of an antigen 350 of a pathogen being sensed. The controller 200 may use a voltage sensor to sense the change in conductivity of the sensor 300. The controller 200 may compare the signal to a pre-determined threshold value. For example, a significant change in conductivity may indicate the antigen 350 is present and the sample is positive. For example, no change in conductivity or an insignificant change in conductivity may indicate the pathogen is absent, and the sample is negative. Based on the presence of the antigen 350, the controller 200 may determine that a pathogen is present. For example, the spike protein of an antibody 340 may be associated with a common human coronavirus SARS-CoV-2 antigen, which is responsible for the COVID-19 vims. When a sample containing SARS-CoV-2 is introduced to the sensor 300, the AV/V0may indicate the presence of the SARS-CoV-2 by demonstrating an increase in conductivity with a higher voltage passing through the EG.
[0064] Next, at step 1040, the controller 200 displays whether the pathogen is present or absent. For example, the display 130 (FIG. 1) may display that the pathogen is present in the sample by showing an increase in voltage flowing through the conductive EG layer 320 of sensor 300. In another example, the sensor 300 may be configured to sense SARS-CoV-2, the antigen 350 responsible for the COVID-19 pathogen. The antibody EG heterostmcture may consist of an antibody 340 associated with SARS-CoV-2, which may change the EG configuration to be more conductive and to pass more voltage through the conductive EG layer 320 when a SARS-CoV-2
antigen is present in the sample. The sensor 300 may provide the benefit of real-time ultra sensitive sensing of pathogens.
[0065] In aspects, the sensor 300 may be reusable. The sensor 300 may be cleaned and reused by heating the sensor 300 to a temperature greater than about 40°C. The sensor 300 may also be cleaned for reuse by soaking the sensor 300 in a salt solution.
[0066] In aspects, the controller 200 is configured to wirelessly transmit (e.g., by Bluetooth™ or other wireless protocol) the data to a smartphone application. In aspects, the data may be wirelessly transmitted (securely) to other types of authorized systems/devices, including but not limited to local health monitoring devices, remote health monitoring systems (e.g., cloud- based and perhaps operated by a healthcare provider), and/or a combination of a local health monitoring device that provides health monitoring information to a health monitoring system. [0067] Certain aspects of the present disclosure may include some, all, or none of the above advantages and/or one or more other advantages readily apparent to those skilled in the art from the drawings, descriptions, and claims included herein. Moreover, while specific advantages have been enumerated above, the various aspects of the present disclosure may include all, some, or none of the enumerated advantages and/or other advantages not specifically enumerated above.
[0068] The aspects disclosed herein are examples of the disclosure and may be embodied in various forms. For instance, although certain aspects herein are described as separate aspects, each of the aspects herein may be combined with one or more of the other aspects herein. Specific structural and functional details disclosed herein are not to be interpreted as limiting, but as a basis for the claims and as a representative basis for teaching one skilled in the art to variously employ the present disclosure in virtually any appropriately detailed structure. Like
reference numerals may refer to similar or identical elements throughout the description of the figures.
[0069] The phrases “in an aspect,” “in aspects,” “in various aspects,” “in some aspects,” or “in other aspects” may each refer to one or more of the same or different example Aspects provided in the present disclosure. A phrase in the form “A or B” means “(A), (B), or (A and
B).” A phrase in the form “at least one of A, B, or C” means “(A); (B); (C); (A and B); (A and
C); (B and C); or (A, B, and C).”
[0070] It should be understood that the foregoing description is only illustrative of the present disclosure. Various alternatives and modifications can be devised by those skilled in the art without departing from the disclosure. For example, while described with respect to an antibody to an antigen on the pathogen, it should be understood that any specific binding pair (e.g., not involving antibodies) may be used for detection in the present systems. Accordingly, the present disclosure is intended to embrace all such alternatives, modifications, and variances. The aspects described with reference to the attached drawing figures are presented only to demonstrate certain examples of the disclosure. Other elements, steps, methods, and techniques that are insubstantially different from those described above and/or in the appended claims are also intended to be within the scope of the disclosure.
Claims
1. A system for detecting a pathogen, the system comprising: a sensor configured to generate a signal indicating a conductivity of the sensor; a processor; and a memory including instructions stored thereon, which, when executed by the processor, cause the system to: receive the signal from the sensor; determine a change in a conductivity of the sensor based on the signal; and determine the presence or the absence of a pathogen based on the determined change in conductivity.
2. The system of claim 1, wherein the sensor includes quasi-freestanding bilayer epitaxial graphene.
3. The system of claim 1, wherein the instructions, when executed by the processor, further cause the system to compare the signal to a pre-determined threshold conductivity value.
4. The system of claim 1, the system further including a display, and wherein the instructions, when executed by the processor, further cause the system to display the determined presence or absence of the pathogen.
5. The system of claim 1, wherein the sensor includes: a first layer including a non-conductive material; a second layer including a conductive material having an antibody bonded thereto; and a set of electrodes disposed on the second layer.
6. The system of claim 5, wherein the antibody is bonded to the conductive material via a crosslinker.
7. The system of claim 5, wherein the set of electrodes is configured to supply a charge to the conductive material in the sensor.
8. The system of claim 5, wherein the antibody corresponds to an antigen to be sensed.
9. The system of claim 5, wherein the sensor is reusable.
10. The system of claim 1, wherein the instructions, when executed by the processor, further cause the system to transmit an indication of the determined presence or absence of the pathogen to a user device.
11. A sensor for detecting an antigen, the sensor comprising: a first layer including a non-conductive material;
a second layer including a conductive material having an antibody bonded thereto; and a set of electrodes disposed on the second layer.
12. The sensor of claim 11, wherein the first layer and second layer are formed using thermal decomposition.
13. The sensor of claim 11, wherein the conductive material includes quasi-freestanding bilayer epitaxial graphene.
14. The sensor of claim 11, wherein the set of electrodes is configured to supply a charge to the conductive material.
15. The sensor of claim 11, wherein the antibody corresponds to an antigen to be sensed.
16. The sensor of claim 11, wherein the antibody is chemically bonded to the conductive material via a crosslinker.
17. The sensor of claim 11, wherein the sensor is configured to generate a signal indicating a conductivity of the sensor.
18. A computer-implemented method for pathogen detection comprising: determining a change in a conductivity of a graphene-based sensor; and
determining the presence or the absence of a pathogen based on the determined change in conductivity.
19. The computer- implemented method of claim 18, further comprising supplying a charge to a conductive material of the graphene-based sensor using a set of electrodes.
20. The computer- implemented method of claim 18, further comprising displaying on a user device the determined presence of the pathogen.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US202163223919P | 2021-07-20 | 2021-07-20 | |
US63/223,919 | 2021-07-20 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2023003927A1 true WO2023003927A1 (en) | 2023-01-26 |
Family
ID=84979587
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2022/037666 WO2023003927A1 (en) | 2021-07-20 | 2022-07-20 | Systems and methods for pathogen detection |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2023003927A1 (en) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080314766A1 (en) * | 2007-06-20 | 2008-12-25 | Board Of Trustees Of Michigan State University | Electrically-active ferromagnetic particle conductimetric biosensor test kit |
US20130217598A1 (en) * | 2012-02-06 | 2013-08-22 | Lester F. Ludwig | Microprocessor-controlled microfluidic platform for pathogen, toxin, biomarker, and chemical detection with removable updatable sensor array for food and water safety, medical, and laboratory applications |
EP3070754A1 (en) * | 2015-03-17 | 2016-09-21 | Instytut Technologii Materialów Elektronicznych | A Hall effect element |
US20160306934A1 (en) * | 2015-04-20 | 2016-10-20 | Cardeya Corporation | Pathogen Detection And Display System |
US20180038815A1 (en) * | 2014-12-16 | 2018-02-08 | Northeastern University | Nanotube-Based Biosensor for Pathogen Detection |
US20190284615A1 (en) * | 2018-01-29 | 2019-09-19 | Rite Taste, LLC | Methods and devices for detection of pathogens |
-
2022
- 2022-07-20 WO PCT/US2022/037666 patent/WO2023003927A1/en unknown
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080314766A1 (en) * | 2007-06-20 | 2008-12-25 | Board Of Trustees Of Michigan State University | Electrically-active ferromagnetic particle conductimetric biosensor test kit |
US20130217598A1 (en) * | 2012-02-06 | 2013-08-22 | Lester F. Ludwig | Microprocessor-controlled microfluidic platform for pathogen, toxin, biomarker, and chemical detection with removable updatable sensor array for food and water safety, medical, and laboratory applications |
US20180038815A1 (en) * | 2014-12-16 | 2018-02-08 | Northeastern University | Nanotube-Based Biosensor for Pathogen Detection |
EP3070754A1 (en) * | 2015-03-17 | 2016-09-21 | Instytut Technologii Materialów Elektronicznych | A Hall effect element |
US20160306934A1 (en) * | 2015-04-20 | 2016-10-20 | Cardeya Corporation | Pathogen Detection And Display System |
US20190284615A1 (en) * | 2018-01-29 | 2019-09-19 | Rite Taste, LLC | Methods and devices for detection of pathogens |
Non-Patent Citations (1)
Title |
---|
KIM SOARAM, RYU HEEJU, TAI SHELDON, PEDOWITZ MICHAEL, RZASA JOHN ROBERTSON, PENNACHIO DANIEL J., HAJZUS JENIFER R., MILTON DONALD : "Real-time ultra-sensitive detection of SARS-CoV-2 by quasi-freestanding epitaxial graphene-based biosensor", BIOSENSORS AND BIOELECTRONICS, ELSEVIER SCIENCE LTD, UK, AMSTERDAM , NL, vol. 197, 1 February 2022 (2022-02-01), Amsterdam , NL , pages 113803, XP093027930, ISSN: 0956-5663, DOI: 10.1016/j.bios.2021.113803 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Zhang et al. | Electrical probing of COVID-19 spike protein receptor binding domain via a graphene field-effect transistor | |
Li et al. | Microfluidic magneto immunosensor for rapid, high sensitivity measurements of SARS-CoV-2 nucleocapsid protein in serum | |
Wang et al. | A flexible and regenerative aptameric graphene–nafion biosensor for cytokine storm biomarker monitoring in undiluted biofluids toward wearable applications | |
Hwang et al. | Ultrasensitive detection of dopamine, IL‐6 and SARS‐CoV‐2 proteins on crumpled graphene FET biosensor | |
Hao et al. | An intelligent graphene‐based biosensing device for cytokine storm syndrome biomarkers detection in human biofluids | |
Bisoffi et al. | Detection of viral bioagents using a shear horizontal surface acoustic wave biosensor | |
Islam et al. | A smart nanosensor for the detection of human immunodeficiency virus and associated cardiovascular and arthritis diseases using functionalized graphene-based transistors | |
Oh et al. | A carbon nanotube metal semiconductor field effect transistor-based biosensor for detection of amyloid-beta in human serum | |
Afsahi et al. | Novel graphene-based biosensor for early detection of Zika virus infection | |
Myung et al. | Graphene-encapsulated nanoparticle-based biosensor for the selective detection of cancer biomarkers | |
Peh et al. | Dengue virus detection using impedance measured across nanoporous aluminamembrane | |
Lerner et al. | Detecting Lyme disease using antibody-functionalized single-walled carbon nanotube transistors | |
Nguyen et al. | COVID-19 spike protein induced phononic modification in antibody-coupled graphene for viral detection application | |
Li et al. | Systematic evaluation of IgG responses to SARS-CoV-2 spike protein-derived peptides for monitoring COVID-19 patients | |
Ban et al. | Rapid self-test of unprocessed viruses of SARS-CoV-2 and its variants in saliva by portable wireless graphene biosensor | |
WO2009005542A2 (en) | Detection of bioagents using a shear horizontal surface acoustic wave biosensor | |
Yang et al. | IGZO-TFT biosensors for Epstein–Barr virus protein detection | |
Lin et al. | A Tri‐Channel Oxide Transistor Concept for the Rapid Detection of Biomolecules Including the SARS‐CoV‐2 Spike Protein | |
Luo et al. | Real-time detection of cardiac troponin I and mechanism analysis of AlGaAs/GaAs high electron mobility transistor biosensor | |
Pohanka | Piezoelectric immunosensor for the determination of C-Reactive protein | |
Zhou et al. | Highly sensitive, label-free and real-time detection of alpha-fetoprotein using a silicon nanowire biosensor | |
WO2023003927A1 (en) | Systems and methods for pathogen detection | |
JP2023548777A (en) | Systems, devices and methods for virus monitoring in wastewater | |
Yuan et al. | A cost-effective smartphone-based device for rapid C-reaction protein (CRP) detection using magnetoelastic immunosensor | |
Ozturk et al. | Cross-sectional IgM and IgG profiles in SARS-CoV-2 infection |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22846543 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |